Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells

Sorafenib, an oral multi-tyrosine kinase inhibitor, has been the first-line therapy for the treatment of patients with advanced HCC, providing a survival benefit of only three months in approximately 30% of patients. Cancer stem cells (CSCs) are a rare tumour subpopulation with self-renewal and diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, Ritu, Bridle, Kim R., Cao, Lu, Crawford, Darrell H. G., Jayachandran, Aparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293268/
https://www.ncbi.nlm.nih.gov/pubmed/34208001
http://dx.doi.org/10.3390/curroncol28030200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293268/
https://www.ncbi.nlm.nih.gov/pubmed/34208001
http://dx.doi.org/10.3390/curroncol28030200

Ejemplares similares